Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Irritable bowel syndrome.

Antonella Spinelli1

  • 1Department of Gastroenterology and Digestive Endoscopy, Policlinico di Monza, Monza, Italy. antonella.spinelli@ospedaleniguarda.it

Clinical Drug Investigation
|December 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Ranolazine: established indications and emerging therapeutic potential].

Giornale italiano di cardiologia (2006)·2026
Same author

The effectiveness of serious games for training of attention and executive functions: a systematic review.

Frontiers in child and adolescent psychiatry·2026
Same author

[Sudden cardiac death risk after newly diagnosed cardiomyopathy: insights from the SCD-PROTECT study and implications for clinical practice].

Giornale italiano di cardiologia (2006)·2026
Same author

[Ten questions about cardiac sarcoidosis].

Giornale italiano di cardiologia (2006)·2026
Same author

Demographic and training variations across cardiology subspecialties in Italy: a national survey.

Journal of cardiovascular medicine (Hagerstown, Md.)·2026
Same author

Beta-Blocker Therapy After Myocardial Infarction: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials.

International journal of molecular sciences·2026
Same journal

Deuruxolitinib: New Approval.

Clinical drug investigation·2026
Same journal

Efficacy, Safety, Quality of Life, and Adherence of Dupilumab in Pediatric Atopic Dermatitis: A Systematic Review.

Clinical drug investigation·2026
Same journal

Optimizing Amiodarone Maintenance Dose to Minimize N-Desethylamiodarone Accumulation and Pulmonary Toxicity: Insights from Machine Learning and Pharmacokinetic Simulation.

Clinical drug investigation·2026
Same journal

Assessment of Dose Proportionality and the Effect of Food on a Once-Daily Extended-Release Tablet Formulation of Deutetrabenazine in Healthy Participants.

Clinical drug investigation·2026
Same journal

Ketamine and Evolving Neuroplasticity.

Clinical drug investigation·2026
Same journal

Amyloid-Related Imaging Abnormalities in Anti-amyloid Therapy: Clinical Implications of Kinetics for Safer Use and Risk Stratification.

Clinical drug investigation·2026
See all related articles

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder. Otilonium bromide offers a safe and effective treatment option for IBS symptoms like abdominal pain and diarrhea, with a favorable safety profile.

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Irritable bowel syndrome (IBS) affects 10-15% globally, causing abdominal pain and altered bowel habits.
  • Current IBS treatments primarily manage symptoms, with limited options addressing complex pathophysiology.
  • Serotonergic agents, while explored, carry risks like ischemic colitis, highlighting the need for safer alternatives.

Purpose of the Study:

  • To review the pathophysiology and treatment of IBS.
  • To focus on the role of otilonium bromide in managing IBS symptoms.
  • To explore potential combination therapy with benzodiazepines for IBS.

Main Methods:

  • Review of clinical trials and postmarketing safety data for otilonium bromide.
  • Analysis of existing literature on IBS pathophysiology and treatment strategies.

Related Experiment Videos

  • Examination of the efficacy of otilonium bromide in managing abdominal pain, distension, and diarrhea.

    • Main Results:

    • Otilonium bromide is effective and safe for managing IBS abdominal pain and diarrhea.
    • Clinical trials show otilonium bromide improves abdominal pain and distension.
    • Postmarketing data indicates a favorable safety profile for otilonium bromide, comparable to placebo.

    Conclusions:

    • Otilonium bromide is a well-tolerated and effective spasmolytic agent for IBS symptom management.
    • Combination therapy with benzodiazepines may offer enhanced efficacy but requires further research.
    • There is a continued need for safe and effective IBS treatments addressing its complex pathophysiology.